No connection

Search Results

GILD vs JNJ

GILD
Gilead Sciences, Inc.
NEUTRAL
Price
$132.90
Market Cap
$164.96B
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GILD
19.6
JNJ
21.55
Forward P/E
GILD
13.81
JNJ
18.9
P/B Ratio
GILD
7.27
JNJ
7.03
P/S Ratio
GILD
5.6
JNJ
6.09
EV/EBITDA
GILD
12.4
JNJ
17.81

Profitability

Gross Margin
GILD
78.84%
JNJ
68.08%
Operating Margin
GILD
37.38%
JNJ
23.97%
Profit Margin
GILD
28.9%
JNJ
28.46%
ROE
GILD
40.66%
JNJ
35.03%
ROA
GILD
12.52%
JNJ
8.68%

Growth

Revenue Growth
GILD
4.7%
JNJ
9.1%
Earnings Growth
GILD
23.4%
JNJ
48.6%

Financial Health

Debt/Equity
GILD
1.13
JNJ
0.6
Current Ratio
GILD
1.55
JNJ
1.03
Quick Ratio
GILD
1.23
JNJ
0.69

Dividends

Dividend Yield
GILD
2.47%
JNJ
2.19%
Payout Ratio
GILD
46.61%
JNJ
46.6%

AI Verdict

GILD NEUTRAL

GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.

Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

GILD vs JNJ: Head-to-Head Comparison

This page compares Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile